Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (221-230 of 550) with videos related to

Pageof 55
Sort By:
Cancer|September 10, 2008
A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancerPhilippe A Cassier, Isabelle Ray-Coquard, Marie-Pierre Sunyach, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 29, 2025
Mucinous ovarian carcinoma: Impact of ovarian stimulation, hormonal contraception, and hormone replacement therapyChloé Barbier de Reulle, Marine Rebotier, Nicolas Chopin, et al.
Histopathology|June 3, 2015
DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group studyThibault Goulvent, Isabelle Ray-Coquard, Stéphane Borel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2022
Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcomaBenoît Allignet, Waisse Waissi, Xavier Geets, et al.
Cancer Medicine|March 28, 2019
Very long-term survivors among patients with metastatic soft tissue sarcomaMélodie Carbonnaux, Mehdi Brahmi, Camille Schiffler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomasCharlie Gourley, John Farley, Diane M Provencher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2023
Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal TreatmentRoberta Sanfilippo, Marta Sbaraglia, Chiara Fabbroni, et al.
Gynecologic Oncology|July 10, 2012
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinomaUrsula A Matulonis, Sudarshan Sharma, Sharad Ghamande, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumorsIsabelle Ray-Coquard, Jubilee Brown, Philipp Harter, et al.
BMC Cancer|December 19, 2012
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trialDavid Pérol, Jocelyne Provençal, Anne-Claire Hardy-Bessard, et al.
Pageof 55

Showing results (221-230 of 550) with videos related to

Sort By:
Pageof 55
Cancer|September 10, 2008
A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancerPhilippe A Cassier, Isabelle Ray-Coquard, Marie-Pierre Sunyach, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 29, 2025
Mucinous ovarian carcinoma: Impact of ovarian stimulation, hormonal contraception, and hormone replacement therapyChloé Barbier de Reulle, Marine Rebotier, Nicolas Chopin, et al.
Histopathology|June 3, 2015
DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group studyThibault Goulvent, Isabelle Ray-Coquard, Stéphane Borel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2022
Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcomaBenoît Allignet, Waisse Waissi, Xavier Geets, et al.
Cancer Medicine|March 28, 2019
Very long-term survivors among patients with metastatic soft tissue sarcomaMélodie Carbonnaux, Mehdi Brahmi, Camille Schiffler, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomasCharlie Gourley, John Farley, Diane M Provencher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2023
Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal TreatmentRoberta Sanfilippo, Marta Sbaraglia, Chiara Fabbroni, et al.
Gynecologic Oncology|July 10, 2012
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinomaUrsula A Matulonis, Sudarshan Sharma, Sharad Ghamande, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumorsIsabelle Ray-Coquard, Jubilee Brown, Philipp Harter, et al.
BMC Cancer|December 19, 2012
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trialDavid Pérol, Jocelyne Provençal, Anne-Claire Hardy-Bessard, et al.
Pageof 55